BUSINESS GOAL:

Increase awareness about PROVENGE® (sipuleucel-T) for metastatic, castrate-resistant prostate cancer as an important treatment option which utilizes the patient’s own immune system and extends survival.

OBJECTIVE:

Communicate the clinical value and efficacy of PROVENGE to healthcare professionals, including oncologists, hematologists, and urologists.

Click here to read the full case study in PDF format.